美国 · 平台与数据 · MarketBeat

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

来源：MarketBeat · 美国 59 分钟前

Morgan Stanley increased their price objective on Kymera Therapeutics from $135.00 to $146.00 and gave the stock an "overweight" rating in a research report on Tuesday.

在 MarketBeat 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.marketbeat.com)

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

推荐阅读

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Target Raised at Morgan Stanley

分享

推荐阅读

Here's How Much a $10,000 Investment in Realty Income Will Get You in Monthly Dividends

My wife cried when I found out she had only $80,000 in her 401(k). I have $2.2 million. Am I wrong to be shocked?

Best Stocks Under $5

Novartis Raises Guidance After Trial Setbacks Hit Profit

Walmart copies a core Costco move that also benefits customers

ATOSS Software Q3 2026 Earnings Call Is Live